主权项 |
1. A compound of formula (I): wherein: each X is N or CR6, where at least one X is N, where each R6 is independently selected from the group consisting of hydrogen, halogen, (C1-C8)alkyl, (C2-C8)alkenyl, (C1-C8)alkynyl, (C1-C8)haloalkyl, —(C1-C4)alkylene-R7, —OR7, —CN, —NO2 and —NR7R7, where each R7 is independently selected from the group consisting of hydrogen and (C1-C8)alkyl, and where each said (C1-C8)alkyl in R6 is optionally substituted by one or more substituents independently selected from the group consisting of halogen, hydroxyl and (C1-C8)alkoxy; Y is Y1-Y2 or Y2-Y1, where Y1 is absent or is selected from the group consisting of (C1-C8)alkylene, (C2-C8)alkenylene, (C1-C8)haloalkylene, (C1-C8)heteroalkylene, and (C2-C8)heteroalkenylene, and where Y1 is optionally substituted with one or more R8 where each R8 is independently selected from the group consisting of halogen, (C1-C10)alkyl, —CN, ═O, —R9—OR9, —SR9 and —NO2, and where each R9 is independently selected from the group consisting of hydrogen, (C1-C8)alkyl, (C3-C10)cycloalkyl, 3-12 membered heterocyclyl, (C6-C12)aryl and 5-12 membered heteroaryl, and where Y2 is absent or oxygen; Z is Z1-Z2, where each of Z1 and Z2 is independently absent or selected from the group consisting of (C1-C8)alkylene, (C2-C8)alkenylene, (C3-C10)cycloalkyl, 3-12 membered heterocyclyl and (C1-C8)heteroalkylene, where Z is optionally independently substituted with one or more R10 where each R10 is independently selected from the group consisting of halogen, (C1-C8)alkyl, —CN, ═O, —OR11 and —NO2, and where each R11 is independently selected from the group consisting of hydrogen, (C1-C8)alkyl, (C3-C10)cycloalkyl, 3-12 membered heterocyclyl, (C6-C12)aryl and 5-12 membered heteroaryl; each R1 is independently selected from the group consisting of hydrogen, halogen, (C1-C8)alkyl, (C1-C8)haloalkyl, —(C1-C4alkyl)R7, —OR7, —CN, —C(O)R7, —CO2R7, —C(O)NR7R7, —SOR7, —SO2R7, —SO2NR7R7, —NO2, —NR7R7, —NR7C(O)R7, —NR7C(O)NR7R7, —NR7C(O)OR7, —NR7SO2R7, —NR7SO2NR7R7, —OC(O)R7 and —OC(O)NR7R7; where any set of two R1 on the same or different piperidine carbons optionally join to form a spirocyclic, fused or bridged ring system comprising 1-4 non-piperadine members and 1-2 heteroatoms selected from N, O and S, and where any set of two R1 on adjacent piperidine carbons optionally join to form a carbon-carbon bond; R2 and R3 are each independently selected from the group consisting of hydrogen, halogen, (C1-C8)alkyl, (C1-C8)haloalkyl, (C3-C10)cycloalkyl, 3-12 membered heterocyclyl, —OR13, —NR14R14, —C(O)NR14R14, —SO2NR14R14, —NR14SO2R14, —SO2R14, (C6-C12)aryl and 5-12 membered heteroaryl, where each R13 is independently selected from the group consisting of hydrogen, (C1-C4)alkyl, (C1-C4)haloalkyl, (C3-C10)cycloalkyl, 3-12 membered heterocyclyl, (C6-C12)aryl and 5-12 membered heteroaryl, where each R14 is independently selected from the group consisting of hydrogen, (C1-C8)alkyl, (C3-C10)cycloalkyl, 3-12 membered heterocyclyl, (C6-C12)aryl and 5-12 membered heteroaryl, or two R14 together with the N atom to which they are attached to form a 3-12 membered heterocyclyl or 5-12 membered heteroaryl, each optionally containing 1, 2 or 3 additional heteroatoms selected from O, N and S, and where R2, R3 or both R2 and R3 is optionally substituted with one or more substituents independently selected from halogen, (C1-C8)alkyl, hydroxyl, (C1-C4)alkoxy, —CN, NH2, NH(C1-C4alkyl), N(C1-C4alkyl)2, (C3-C10)cycloalkyl, 3-12 membered heterocyclyl, (C6-C12)aryl and 5-12 membered heteroaryl; or R2 and R3 join to form a heterocyclic ring selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, piperadinonyl, piperazinonyl and morpholinyl, optionally substituted with one or more substituents independently selected from the group consisting of R15 and (C1-C4)alkylene-R15, where R15 is independently selected from the group consisting of halogen, (C1-C4)alkyl, (C1-C4)haloalkyl, hydroxyl, (C1-C4)alkoxy, CN, NH2, NH(C1-C4alkyl), N(C1-C4alkyl)2, (C3-C10)cycloalkyl, 3-12 membered heterocyclyl, (C6-C12)aryl and 5-12 membered heteroaryl; R4 is selected from the group consisting of (C1-C8)alkyl, (C1-C8)haloalkyl, (C3-C10)cycloalkyl, 3-12 membered heterocyclyl and —C(O)NR14R14, where R4 is optionally substituted with one or more R12 independently selected from halogen, hydroxyl, (C1-C4)alkoxy, —CN, NH2, NH(C1-C4alkyl), N(C1-C4alkyl)2, (C3-C10)cycloalkyl, 3-12 membered heterocyclyl, (C6-C12)aryl and 5-12 membered heteroaryl, and where, when R12 is (C1-C4)alkoxy, NH(C1-C4alkyl), N(C1-C4alkyl)2, (C3-C10)cycloalkyl, 3-12 membered heterocyclyl, (C6-C12)aryl or 5-12 membered heteroaryl, it is optionally substituted by one or more substituents independently selected from halogen, hydroxyl, (C1-C4)alkoxy, —CN, NH2, NH(C1-C4alkyl), N(C1-C4alkyl)2, (C3-C10)cycloalkyl, 3-12 membered heterocyclyl, (C6-C12)aryl and 5-12 membered heteroaryl; R5 is a mono- or bi-cyclic aryl or a mono- or bi-cyclic heteroaryl, optionally substituted with one or more substituents independently selected from the group consisting of (C1-C8)alkyl, halogen, (C1-C8)haloalkyl, (C3-C10)cycloalkyl, 3-12 membered heterocyclyl, —OR13, —NR14R14, —C(O)NR14R14, —SO2NR14R14, —SO2R14, —NR14SO2R14, CN, mono- or bi-cyclic aryl and mono- or bi-cyclic heteroaryl, said one or more optional substituents being further optionally substituted with one or more substituents selected from the group consisting of (C1-C8)alkyl, (C1-C8)alkylene-OH, (C1-C8)haloalkyl, (C3-C10)cycloalkyl, 3-12 membered heterocyclyl, —OR13, —NR14R14, —C(O)NR14R14, —SO2NR14R14, —SO2R14, —NR14SO2R14 and CN; and m is 1-9, or a pharmaceutically acceptable salt thereof. |